Breast Imaging Practice Questions

Q: The sensitivity of mammography is low in young females because?

The breast tissue is dense. **Explanation:** The sensitivity of mammography is primarily dependent on the **radiodensity** of the breast tissue. In young females, the breasts are composed of a high proportion of **fibroglandular tissue**, which appears white (radiopaque) on a mammogram. Since most breast cancers and masses also appear white, the dense tissue creates a "masking effect," making it difficult to distinguish a lesion from normal anatomy. * **Why Option C is correct:** As women age, the breast undergoes **fatty involution**, where dense glandular tissue is replaced by fat (which appears dark/radiolucent). In young women, this process has not yet occurred. The lack of contrast between dense tissue and potential tumors leads to a higher rate of false negatives. * **Why Option A is incorrect:** This describes the post-menopausal breast. Less glandular tissue and more fat actually *increase* the sensitivity of mammography. * **Why Option B is incorrect:** Cooperation is rarely a limiting factor for sensitivity; the limitation is purely anatomical and physical. * **Why Option D is incorrect:** While young females do have less fat content, the primary reason for low sensitivity is the presence of dense glandular tissue, which is the specific factor that obscures lesions. **High-Yield Clinical Pearls for NEET-PG:** * **Investigation of Choice (IOC):** For females ** 40 years**. * **BI-RADS:** The Breast Imaging-Reporting and Data System is used to standardize mammogram reporting. * **MRI Breast:** Has the highest sensitivity for detecting breast cancer and is used for screening high-risk patients (e.g., BRCA mutations).

Q: What does a BIRADS score of 4 suggest?

Suspicious of malignancy. **Explanation:** The **BI-RADS (Breast Imaging-Reporting and Data System)** is a standardized scoring system used by radiologists to communicate the risk of malignancy in breast lesions. **Why Option B is Correct:** A **BI-RADS 4** score is defined as **"Suspicious Abnormality."** These lesions do not have the classic appearance of cancer but possess features that make malignancy a possibility. Because the risk of malignancy ranges from **2% to 95%**, a tissue diagnosis (biopsy) is mandatory for all BI-RADS 4 lesions. **Analysis of Incorrect Options:** * **Option A (Normal):** This corresponds to **BI-RADS 1**, where there are no findings to report and the risk of malignancy is 0%. * **Option C (Mostly Benign):** This corresponds to **BI-RADS 3** (Probably Benign). These lesions have a 95% risk). **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS 0:** Incomplete assessment; needs further imaging (e.g., comparison with old films or ultrasound). * **BI-RADS 2:** Benign findings (e.g., simple cysts, stable fibroadenomas); 0% risk of malignancy. * **Sub-classification of BI-RADS 4:** * **4A:** Low suspicion (2–10% risk) * **4B:** Moderate suspicion (10–50% risk) * **4C:** High suspicion (50–95% risk) * **Management Rule:** BI-RADS 4 and 5 always require pathological correlation (Core Needle Biopsy is the gold standard).

Q: Which investigation is used to differentiate between scar tissue and residual or recurrence of a breast tumor?

Magnetic Resonance Imaging (MRI). **Explanation:** The differentiation between post-surgical scar tissue and tumor recurrence is a common clinical challenge. **Magnetic Resonance Imaging (MRI) with Contrast (Gadolinium)** is the investigation of choice for this purpose due to its high sensitivity and the physiological principle of **neoangiogenesis** [2]. 1. **Why MRI is correct:** Malignant tumors exhibit rapid, disordered angiogenesis. When contrast is administered, tumors show **rapid enhancement and early washout** (Kinetic Curve Type III) [1]. In contrast, mature scar tissue is relatively avascular; it typically shows minimal to no enhancement, or very slow, progressive enhancement [1]. This physiological difference allows MRI to distinguish between the two with a high negative predictive value. 2. **Why other options are incorrect:** * **Mammography:** Both scars and tumors can appear as areas of architectural distortion or high-density masses. Mammography cannot reliably distinguish between them, especially in the first 6–12 months post-surgery. * **Ultrasound (USG):** While useful for guided biopsies, both scars and recurrences can appear as hypoechoic areas with posterior acoustic shadowing, leading to diagnostic ambiguity. 3. **High-Yield Clinical Pearls for NEET-PG:** * **Timing:** Post-operative MRI should ideally be performed at least **6 months after radiotherapy** to avoid false positives caused by treatment-induced inflammation. * **BI-RADS:** Breast Imaging-Reporting and Data System is the standard reporting lexicon. * **Gold Standard:** While MRI is the best imaging tool, **Biopsy** remains the definitive gold standard for confirming recurrence. * **Screening:** MRI is also the screening modality of choice for high-risk patients (e.g., BRCA1/2 mutations) [3].

Q: A BIRADS-0 score on mammography indicates:

Requires additional imaging or prior examinations. **Explanation:** The **BI-RADS (Breast Imaging-Reporting and Data System)** is a standardized scoring system developed by the American College of Radiology to communicate breast imaging findings and risk of malignancy. **Why Option D is correct:** A **BI-RADS 0** score signifies an **incomplete assessment**. It is used when the current mammogram does not provide enough information to make a definitive diagnosis. This usually occurs in screening settings where the radiologist needs: 1. **Additional imaging:** Such as spot compression views, magnification views, or a complementary ultrasound. 2. **Comparison with prior films:** To determine if a finding is new or stable over time. **Why other options are incorrect:** * **Option A (Negative):** This corresponds to **BI-RADS 1**, where the breasts are symmetrical with no masses or suspicious calcifications. * **Option B (Benign):** This corresponds to **BI-RADS 2**, where findings like secretory calcifications or simple cysts are present but have 0% risk of malignancy. * **Option C (Suspicious):** This corresponds to **BI-RADS 4**, which carries a 2% to 95% risk of malignancy and requires a tissue biopsy. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS 3:** Probably benign ( 95% risk); requires appropriate action (biopsy/surgery). * **BI-RADS 6:** Known biopsy-proven malignancy; used for monitoring response to neoadjuvant chemotherapy. * **Management:** BI-RADS 4 and 5 always necessitate a biopsy. BI-RADS 0 is the only category that is "incomplete" and requires further diagnostic workup before a final category (1–5) can be assigned.

Q: What is the preferred investigation for the evaluation of a suspected breast mass in a patient with a breast implant?

Magnetic Resonance Imaging (MRI). **Explanation:** **1. Why MRI is the Correct Answer:** Magnetic Resonance Imaging (MRI) is the **gold standard** and the most sensitive investigation for evaluating breast masses in patients with implants. The presence of an implant (silicone or saline) creates significant diagnostic challenges on conventional imaging. MRI provides superior soft-tissue contrast and allows for the visualization of breast parenchyma behind and around the implant without the risk of implant rupture. Furthermore, it is the investigation of choice for detecting **implant-related complications** (e.g., intracapsular or extracapsular rupture) while simultaneously screening for malignancy. **2. Why Other Options are Incorrect:** * **Mammography:** While it can be performed using specialized **Eklund views** (implant displacement techniques), the implant material is radiopaque and can obscure up to 25% of the breast tissue, leading to a high false-negative rate. There is also a theoretical risk of implant rupture during compression. * **Ultrasound (USG):** USG is useful for distinguishing cysts from solid masses and is the first-line tool for "snowstorm" appearances in extracapsular leaks. However, it is operator-dependent and lacks the sensitivity of MRI for comprehensive parenchymal evaluation in the presence of an implant. **3. Clinical Pearls for NEET-PG:** * **Linguine Sign:** A classic MRI finding indicating **intracapsular rupture** (collapsed elastomer shell floating in silicone). * **Snowstorm Appearance:** A classic USG finding indicating **extracapsular silicone leakage** into the axillary lymph nodes or tissues. * **BI-RADS 0:** If a mammogram is inconclusive due to an implant, the next step is often MRI. * **Screening:** For routine cancer screening in patients with implants, mammography with Eklund views is still the initial step, but for **diagnostic evaluation of a mass**, MRI is preferred.

Q: Which of the following is seen in carcinoma breast?

Pleomorphic calcification. **Explanation:** In breast imaging, microcalcifications are a critical mammographic finding. The morphology of these calcifications is the most reliable indicator of whether a lesion is benign or malignant. **1. Why Pleomorphic Calcification is Correct:** **Pleomorphic (or fine pleomorphic)** calcifications are highly suggestive of malignancy (BI-RADS 4 or 5). They are characterized by varying shapes, sizes, and densities, often appearing like "broken glass" or "crushed stones." These occur when necrotic tumor cells in a duct (especially in **Ductal Carcinoma In Situ - DCIS**) undergo mineralization. Their irregular nature reflects the disordered growth and necrosis typical of cancer. **2. Analysis of Incorrect Options:** * **A. Powdery Calcification:** These are very fine, indistinct calcifications. While they can be seen in some malignancies, they are less specific than pleomorphic ones and are often associated with benign sclerosing adenosis. * **B. Popcorn Calcification:** This is a classic "spotter" for **Fibroadenoma**. These are large, coarse calcifications that occur as a fibroadenoma undergoes involution/degeneration. * **C. Nodular Calcification:** Also known as "coarse" or "round" calcifications, these are typically associated with benign processes like fat necrosis or old plasma cell mastitis. **3. High-Yield Clinical Pearls for NEET-PG:** * **Linear/Branching (Casting) Calcifications:** These are the most suspicious for high-grade DCIS (Comedocarcinoma), representing calcified necrotic debris within the ductal lumen. * **Egg-shell/Rim Calcification:** Classically seen in **Fat Necrosis** or simple cysts. * **Tea-cupping (Milk of Calcium):** Seen on the lateral view mammogram, indicating benign fibrocystic changes. * **BI-RADS:** Remember that BI-RADS 5 has a >95% probability of malignancy, and pleomorphic/linear branching calcifications are its hallmarks.

Q: BIRADS score 5 is:

Highly suggestive of malignancy. **Explanation:** The **BI-RADS (Breast Imaging-Reporting and Data System)** is a standardized classification system developed by the American College of Radiology (ACR) to provide a uniform language for reporting breast findings and guiding clinical management. **Correct Answer: D. Highly suggestive of malignancy** A **BI-RADS 5** assessment is reserved for lesions that have a classic appearance of cancer. The probability of malignancy in this category is **≥ 95%**. Findings typically include spiked or spiculated masses, pleomorphic calcifications, and skin retraction. The standard management is a mandatory biopsy. **Analysis of Incorrect Options:** * **A. Negative (BI-RADS 1):** This indicates a normal exam with no masses, architectural distortion, or suspicious calcifications. The risk of malignancy is 0%. * **B. Probably benign (BI-RADS 3):** These findings have a very low risk of malignancy (**< 2%**). Examples include non-palpable, circumscribed solid masses. Management involves short-interval follow-up (usually 6 months) rather than immediate biopsy. * **C. Suspicious abnormality (BI-RADS 4):** This category covers a wide range of risk (**2% to 95%**) and is further subdivided into 4A (low), 4B (moderate), and 4C (high suspicion). Biopsy is required. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS 0:** Incomplete; needs further imaging (e.g., additional views or ultrasound). * **BI-RADS 2:** Benign findings (e.g., simple cysts, stable fibroadenomas, or secretory calcifications). Risk is 0%. * **BI-RADS 6:** Known biopsy-proven malignancy; used for imaging done after a diagnosis but before definitive treatment (like surgery or chemotherapy). * **Management Rule:** BI-RADS 4 and 5 always require tissue diagnosis (biopsy).

Q: What is the recommendation for BI-RADS 4 classification?

Tissue diagnosis. The **BI-RADS (Breast Imaging-Reporting and Data System)** is a standardized scoring system used to communicate the risk of malignancy in breast imaging. ### **Explanation of the Correct Answer** **BI-RADS 4** is defined as **"Suspicious Abnormality."** Lesions in this category do not have the classic appearance of malignancy but have a sufficiently high probability of being cancer (**>2% to <95%**) that a definitive diagnosis is required. Therefore, the management recommendation is **Tissue Diagnosis** (usually via Core Needle Biopsy) to rule out malignancy. ### **Analysis of Incorrect Options** * **A. Regular Follow-up:** This is the management for **BI-RADS 1 (Normal)** and **BI-RADS 2 (Benign)**, where the risk of malignancy is 0%. * **C. Short Interval Follow-up:** This is the management for **BI-RADS 3 (Probably Benign)**. It involves a 6-month follow-up to ensure stability, as the risk of malignancy is **≤2%**. * **D. Excision:** While some BI-RADS 4 lesions may eventually require surgical excision (if biopsy shows high-risk lesions like ADH), the *immediate* next step is a needle biopsy (tissue diagnosis), not primary surgical excision. **BI-RADS 5** (>95% risk) often proceeds directly to definitive treatment planning. ### **High-Yield Clinical Pearls for NEET-PG** * **BI-RADS 0:** Incomplete; needs further imaging (e.g., spot compression, ultrasound). * **BI-RADS 4 Sub-categories:** * **4A:** Low suspicion (2–10%) * **4B:** Moderate suspicion (10–50%) * **4C:** High suspicion (50–95%) * **BI-RADS 6:** Known biopsy-proven malignancy; used for monitoring response to neoadjuvant chemotherapy. * **Gold Standard:** For most BI-RADS 4/5 lesions, **Ultrasound-guided Core Needle Biopsy** is preferred over FNAC.

Q: Which of the following is seen in carcinoma of the breast?

Pleomorphic calcification. **Explanation:** In breast imaging, **calcifications** are categorized based on their morphology and distribution to assess the risk of malignancy. **Why Pleomorphic Calcification is Correct:** **Pleomorphic calcifications** (specifically "fine pleomorphic") are highly suspicious for malignancy (BI-RADS 4 or 5). They vary in size, shape, and density, often appearing as "crushed stone" or irregular fragments. These occur when necrotic debris within a malignant duct (as seen in **Ductal Carcinoma in Situ - DCIS**) undergoes mineralization. Their irregular nature reflects the disordered growth and necrosis of cancer cells. **Analysis of Incorrect Options:** * **A. Powdery Calcification:** These are fine, indistinct "cotton wool" appearances. While they can be seen in sclerosing adenosis, they are generally considered "amorphous" and have a lower specificity for cancer compared to pleomorphic types. * **B. Popcorn Calcification:** This is a classic "spotter" for **Involuting Fibroadenoma**. These are large, coarse, and dense calcifications (>2-3 mm) and are pathognomonic for a benign process. * **C. Nodular/Coarse Calcification:** These are typically associated with benign conditions like fat necrosis or old trauma. **High-Yield Clinical Pearls for NEET-PG:** * **BI-RADS Classification:** Calcifications are the primary feature used to detect DCIS on mammography. * **Malignant Patterns:** Fine pleomorphic, fine linear, or branching (casting) calcifications are the most worrisome for malignancy. * **Benign Patterns:** Eggshell/rim calcification (Fat necrosis/Cysts), Rail-track (Arterial atherosclerosis), and Milk of calcium (Tea-cup sign on lateral view). * **Gold Standard:** Mammography is the best initial screening tool for microcalcifications; Ultrasound is generally poor at detecting them.

Question 1

The sensitivity of mammography is low in young females because?

Accepted Answer

The breast tissue is dense

Answer

There is less glandular tissue and more fat

Answer

Young females are less cooperative

Answer

There is less fat content

Question 2

What does a BIRADS score of 4 suggest?

Accepted Answer

Suspicious of malignancy

Answer

Normal lesion

Answer

Mostly benign

Answer

Proven malignancy

Question 3

All of the following statements about mammography are TRUE, EXCEPT:

Accepted Answer

It has a high positive predictive value.

Answer

Low energy X-rays are used.

Answer

It is a screening and diagnostic tool.

Answer

The specificity of mammography is 95%.

Question 4

Which investigation is used to differentiate between scar tissue and residual or recurrence of a breast tumor?

Accepted Answer

Magnetic Resonance Imaging (MRI)

Answer

Ultrasound (USG)

Answer

Mammography

Answer

All of the above

Question 5

A BIRADS-0 score on mammography indicates:

Accepted Answer

Requires additional imaging or prior examinations

Answer

Negative for cancer

Answer

Benign

Answer

Suspicious for malignancy

Question 6

What is the preferred investigation for the evaluation of a suspected breast mass in a patient with a breast implant?

Accepted Answer

Magnetic Resonance Imaging (MRI)

Answer

Ultrasound (USG)

Answer

Mammography

Answer

All of the above

Question 7

Which of the following is seen in carcinoma breast?

Accepted Answer

Pleomorphic calcification

Answer

Powdery calcification

Answer

Popcorn calcification

Answer

Nodular calcification

Question 8

BIRADS score 5 is:

Accepted Answer

Highly suggestive of malignancy

Answer

Negative

Answer

Probably benign

Answer

Suspicious abnormality

Question 9

What is the recommendation for BI-RADS 4 classification?

Accepted Answer

Tissue diagnosis

Answer

Regular follow up

Answer

Short interval follow up

Answer

Excision

Question 10

Which of the following is seen in carcinoma of the breast?

Accepted Answer

Pleomorphic calcification

Answer

Powdery calcification

Answer

Popcorn calcification

Answer

Nodular calcification

Breast Imaging — MCQs

Breast Imaging — MCQs

On this page

Practice by Chapter

Want unlimited practice?